AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 116 filers reported holding AUDENTES THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 1.14 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $569,000 | -98.2% | 9,512 | -99.1% | 0.00% | -97.5% |
| Q3 2019 | $31,307,000 | -8.5% | 1,114,529 | +23.3% | 0.04% | -42.0% |
| Q2 2019 | $34,233,000 | -0.4% | 904,221 | +2.7% | 0.07% | -11.5% |
| Q1 2019 | $34,361,000 | +86.8% | 880,601 | +2.1% | 0.08% | +69.6% |
| Q4 2018 | $18,390,000 | -39.0% | 862,561 | +13.3% | 0.05% | -25.8% |
| Q3 2018 | $30,142,000 | +6.7% | 761,361 | +3.0% | 0.06% | +3.3% |
| Q2 2018 | $28,246,000 | +71.7% | 739,241 | +35.1% | 0.06% | +66.7% |
| Q1 2018 | $16,446,000 | +500.2% | 547,291 | +524.2% | 0.04% | +500.0% |
| Q4 2017 | $2,740,000 | +37.4% | 87,674 | +23.2% | 0.01% | +50.0% |
| Q3 2017 | $1,994,000 | +42.7% | 71,174 | -2.5% | 0.00% | +33.3% |
| Q2 2017 | $1,397,000 | +11.0% | 73,024 | -1.2% | 0.00% | 0.0% |
| Q1 2017 | $1,259,000 | +138.4% | 73,914 | +155.8% | 0.00% | +200.0% |
| Q4 2016 | $528,000 | -17.6% | 28,890 | -19.8% | 0.00% | -50.0% |
| Q3 2016 | $641,000 | – | 36,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 1,204,615 | $37,644,219,000 | 39.61% |
| Casdin Capital, LLC | 400,000 | $12,500,000 | 3.04% |
| Opaleye Management Inc. | 210,000 | $6,652,000 | 2.13% |
| Orbimed Advisors | 4,129,638 | $129,051,000 | 1.63% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,190,516 | $37,204,000 | 1.46% |
| Redmile Group, LLC | 929,326 | $29,041,000 | 1.26% |
| Cormorant Asset Management, LP | 337,876 | $10,559,000 | 1.10% |
| Perceptive Advisors | 781,309 | $24,416,000 | 0.81% |
| Rock Springs Capital Management LP | 525,000 | $16,406,000 | 0.74% |
| Virtus ETF Advisers LLC | 11,898 | $372,000 | 0.47% |